{"denoms":[{"counts":[{"groupId":"BG000","value":"80"}],"units":"Participants"}],"groups":[{"description":"Participants received sugemalimab (CS1001) 1200 mg intravenously every 3 weeks (Q3W)","id":"BG000","title":"R/R ENKTL"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"}],"title":"<=18 years"},{"measurements":[{"groupId":"BG000","value":"66"}],"title":"Between 18 and 65 years"},{"measurements":[{"groupId":"BG000","value":"14"}],"title":">=65 years"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Age, Categorical","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"12.68","value":"48.1"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"Years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"29"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"51"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"}],"title":"Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"80"}],"title":"Not Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"0"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Ethnicity (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"}],"title":"American Indian or Alaska Native"},{"measurements":[{"groupId":"BG000","value":"80"}],"title":"Asian"},{"measurements":[{"groupId":"BG000","value":"0"}],"title":"Native Hawaiian or Other Pacific Islander"},{"measurements":[{"groupId":"BG000","value":"0"}],"title":"Black or African American"},{"measurements":[{"groupId":"BG000","value":"0"}],"title":"White"},{"measurements":[{"groupId":"BG000","value":"0"}],"title":"More than one race"},{"measurements":[{"groupId":"BG000","value":"0"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"80"}]}],"title":"China"}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Region of Enrollment","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"21"}]}],"title":"0"},{"categories":[{"measurements":[{"groupId":"BG000","value":"59"}]}],"title":"1"}],"description":"0-Fully active, able to carry on all pre-disease performance without restriction. 1-Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g., light house work, office work. 2-Ambulatory and capable of all selfcare but unable to carry out any work activities; up and about more than 50% of waking hours. 3-Capable of only limited selfcare; confined to bed or chair more than 50% of waking hours. 4-Completely disabled; cannot carry on any selfcare; totally confined to bed or chair. 5-Dead","paramType":"COUNT_OF_PARTICIPANTS","title":"Eastern Cooperative Oncology Group Performance Status","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"9"}]}],"title":"Stage I"},{"categories":[{"measurements":[{"groupId":"BG000","value":"17"}]}],"title":"Stage II"},{"categories":[{"measurements":[{"groupId":"BG000","value":"54"}]}],"title":"Stage IV"}],"description":"Based on Ann Arbor classification: Stage I - Involvement: 1 node or a group of adjacent nodes. Extranodal Status: Single extranodal lesion without nodal involvement. Stage II - Involvement: 2 or more nodal groups on the same side of the diaphragm. Extranodal Status: Stage I/II by nodal extent with limited contiguous extranodal involvement. Stage III - Involvement: Nodes on both sides of the diaphragm; nodes above the diaphragm with spleen involvement. Extranodal Status: N/A. Stage IV - Involvement: Additional noncontiguous extralymphatic involvement. Extranodal Status: N/A.","paramType":"COUNT_OF_PARTICIPANTS","title":"Stage of Extranodal Natural Killer/ T-cell Lymphoma at screening","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"44"}]}],"title":"Positive"},{"categories":[{"measurements":[{"groupId":"BG000","value":"36"}]}],"title":"Negative"}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Epstein-Barr Virus (EBV) DNA at Screening","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"5"}]}],"title":"Positive"},{"categories":[{"measurements":[{"groupId":"BG000","value":"73"}]}],"title":"Negative"},{"categories":[{"measurements":[{"groupId":"BG000","value":"2"}]}],"title":"Missing"}],"description":"Assessments were performed at baseline to determine whether a patient had bone marrow involvement by the disease. \"Positive\" indicates the presence of involvement; \"negative\" indicates absence of involvement; \"missing\" indicates results not applicable.","paramType":"COUNT_OF_PARTICIPANTS","title":"Baseline Bone Marrow Assessment Result","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"79"}]}],"title":"Yes"},{"categories":[{"measurements":[{"groupId":"BG000","value":"1"}]}],"title":"No"}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Central Pathology Confirmed ENKTL","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"43"}]}],"title":"Relapsed"},{"categories":[{"measurements":[{"groupId":"BG000","value":"37"}]}],"title":"Refractory"}],"description":"Participants in this study must have relapsed or refractory ENKTL failing asparaginase-based chemotherapy or chemoradiotherapy. \"Relapse\" indicates disease progression after response to the last treatment; \"refractory\" indicates no response to the last treatment.","paramType":"COUNT_OF_PARTICIPANTS","title":"Patient Status","unitOfMeasure":"Participants"}]}